G D Marijn Veerman
Overview
Explore the profile of G D Marijn Veerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heersche N, Lanser D, Muntinghe-Wagenaar M, Mohmaed Ali M, Ulas E, Trooster T, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39617342
Introduction: Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for ALK-positive (ALK+) NSCLC. Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity....
2.
Gulikers J, Veerman G, Jebbink M, Kruithof P, Steendam C, Boosman R, et al.
JTO Clin Res Rep
. 2024 Mar;
5(4):100656.
PMID: 38550297
Introduction: Brain metastases (BM) are common in patients with advanced -mutated (m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic...
3.
Yin A, Veerman G, van Hasselt J, Steendam C, Dubbink H, Guchelaar H, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Feb;
13(4):612-623.
PMID: 38375997
Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with...
4.
Lanser D, Dingemans A, Mathijssen R, Veerman G
J Natl Compr Canc Netw
. 2023 Oct;
21(10):xxiv-xxv.
PMID: 37856223
No abstract available.
5.
van Veelen A, Veerman G, Verschueren M, Gulikers J, Steendam C, Brouns A, et al.
Int J Cancer
. 2023 Oct;
154(2):332-342.
PMID: 37840304
Osimertinib is prescribed to patients with metastatic non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation. Limited data exists on the impact of patient characteristics or osimertinib exposure on...
6.
Lanser D, de Leeuw S, Oomen-de Hoop E, de Bruijn P, Paats M, Dumoulin D, et al.
J Natl Compr Canc Netw
. 2023 Jun;
21(6):645-651.e1.
PMID: 37308124
Background: Alectinib is the keystone treatment in advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). An exposure-response threshold of 435 ng/mL has recently been established, albeit 37% of...
7.
Lanser D, van der Kleij M, Veerman G, Steeghs N, Huitema A, Mathijssen R, et al.
Biomed Pharmacother
. 2023 May;
163:114823.
PMID: 37172331
Polypharmacy is becoming increasingly prevalent in society. Patients with polypharmacy are at greater risk for drug-drug interactions, which can influence the efficacy of treatment. Especially, in oncology this is a...
8.
Brouns A, van Veelen A, Veerman G, Steendam C, Dursun S, van der Leest C, et al.
JTO Clin Res Rep
. 2023 May;
4(5):100513.
PMID: 37168878
Introduction: Bone metastases are frequent in patients with -mutated () NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We...
9.
Veerman G, Boosman R, Jebbink M, Oomen-de Hoop E, van der Wekken A, Bahce I, et al.
EClinicalMedicine
. 2023 May;
59:101955.
PMID: 37125403
Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (m+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimertinib...
10.
de Leeuw S, Pruis M, Sikkema B, Mohseni M, Veerman G, Paats M, et al.
J Thorac Oncol
. 2023 Mar;
18(8):1017-1030.
PMID: 37001858
Introduction: Alectinib is a standard-of-care treatment for metastatic ALK+ NSCLC. Weight gain is an unexplored side effect reported in approximately 10%. To prevent or intervene alectinib-induced weight gain, more insight...